Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (151-160 of 225) with videos related to

Pageof 23
Sort By:
JCO Precision Oncology|August 21, 2019
Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non-Small-Cell Lung CancerErin Bange, Melina E Marmarelis, Wei-Ting Hwang, et al.
Clinical Lung Cancer|May 9, 2017
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III StudiesCorey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, et al.
Practical Radiation Oncology|February 5, 2015
Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating studyEric P Xanthopoulos, Elizabeth Handorf, Charles B Simone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseRamesh Rengan, Rosemarie Mick, Daniel Pryma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trialGeorge R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
American Journal of Clinical Oncology|March 21, 2013
ACR Appropriateness Criteria® radiation therapy for small-cell lung cancerFeng-Ming Kong, Brian E Lally, Joe Yujiao Chang, et al.
Journal of the American College of Radiology : JACR|July 30, 2013
ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intentKenneth E Rosenzweig, Joe Yujiao Chang, Indrin J Chetty, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)Corey J Langer, Mary W Redman, James L Wade, et al.
Pageof 23

Showing results (151-160 of 225) with videos related to

Sort By:
Pageof 23
JCO Precision Oncology|August 21, 2019
Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non-Small-Cell Lung CancerErin Bange, Melina E Marmarelis, Wei-Ting Hwang, et al.
Clinical Lung Cancer|May 9, 2017
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III StudiesCorey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, et al.
Practical Radiation Oncology|February 5, 2015
Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating studyEric P Xanthopoulos, Elizabeth Handorf, Charles B Simone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseRamesh Rengan, Rosemarie Mick, Daniel Pryma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trialGeorge R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
American Journal of Clinical Oncology|March 21, 2013
ACR Appropriateness Criteria® radiation therapy for small-cell lung cancerFeng-Ming Kong, Brian E Lally, Joe Yujiao Chang, et al.
Journal of the American College of Radiology : JACR|July 30, 2013
ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intentKenneth E Rosenzweig, Joe Yujiao Chang, Indrin J Chetty, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)Corey J Langer, Mary W Redman, James L Wade, et al.
Pageof 23